Research Of Clinical Significance About Neoadjuvant Chemotherapy For Stage ?A Non-small-cell Lung Cancer

Objective:To discuss amd study of neoadjuvant chemotherapy for stage IIIA non-small cell lung cancer of cases surgery, postoperative complications, and serum tumor markers CEA,CYFRA21-1 horizontal dynamic changes in patients with, the analysis evaluated the efficacy and clinical significance of prognosis.Methods:This study selected the December 2012 to December 2014 Shanxi Provincial Tumor Hospital in three wards with a team of doctors from IIIA non small cell lung cancer patients with a total of 72 cases as the research object, randomly divided into for two groups:observation group(36 cases) and control group(36 cases), observation group first two courses of neoadjuvant chemotherapy and 4 weeks after surgery, chemotherapy regimen for GP regimen and TP Regimen; the control group underwent surgical treatment. To explore the analysis of the two groups of patients with surgery, postoperative complications, serum tumor markers CEA, CYFRA21-1 changes.Results:1. Neoadjuvant chemotherapy in patients with an objective response rate(CR + PR)was 58.3% Results(21/36), incidence of adverse reactions occurred in patients with neoadjuvant chemotherapy results of 30.6%(11/36).2.Observation group the postoperative serum tumor markers CEA, CYFRA21-1measured values were significantly lower than that of the control group, two groups compared with statistical significance(P < 0.05); observed after neoadjuvant chemotherapy group of CEA, CYFRA21-1 determination value changes in PR group, curative effect was significantly reduced, significant differences, with statistical significance(P < 0.05), in SD group curative effect but no significant changes, the difference was not statistically significant(P > 0.05).3. Observe the operative time(144.3 ± 30.2) min shorter than the control group(169.2± 35.6) min, surgical resection rate is higher, the difference was significant, statistically significant(P <0.05); the observation group surgery the amount of bleeding(292.5 ± 37.4)ml, after 24 h of chest drainage(302.1 ± 145.2) ml and the overall complication rate(18.1%)patients in the control group blood loss(287.3 ± 35.1) ml, after 24 h of chest drainage(288.9 ± 136.7) ml and the overall complication rate(16.7%), no significant difference was not statistically significant(P> 0.05).4. The observation group patients 6 months survival rate(84.9%) to be higher than the survival rate(75.0%), but no significant difference was not statistically significant(P> 0.05);the observation group after 1 year survival rate(69.7%), 2-year survival rate(51.5%) to be higher than 1-year survival rate(47.2%), 2-year survival rate(27.8%), the difference was significant(P <0.05); The median follow-up period was 25 months and 17 months in the observation group and the control group;The observation group and the control group in patients with a median survival time was 22 months and 15 months, the difference was statistically significant(P<0.05).Conclusion:1. IIIA non-small cell lung cancer receiving neoadjuvant chemotherapy compared with immediate surgery can reduce serum levels of tumor markers ?A non-small cell lung cancer,shorten the operation time, improve the surgical resection rate, without increasing postoperative complications the incidence and improve survival after surgery.2. The serum tumor markers CEA, CYFRA21-1 be used to evaluate of patients with non-small cell lung cancer to neoadjuvant chemotherapy.